How stem cell therapy may support nerve regeneration and nerve pain. Evidence-based overview of MSC treatment for peripheral and neurological nerve injury—what research shows, who is suitable, and realistic timelines.
Stem cell therapy—specifically mesenchymal stem cell (MSC) infusion—is being investigated as a complementary approach to support nerve repair and reduce nerve pain in patients with peripheral nerve injury, neuropathy, and certain neurological conditions. Early clinical trials suggest that MSCs may reduce inflammation, support nerve tissue survival, and potentially encourage nerve regeneration through paracrine signalling—the release of anti-inflammatory and growth-promoting molecules. However, nerve regeneration is slow and complex; results vary significantly between patients, and stem cell therapy is not a replacement for conventional nerve care, surgical repair, or rehabilitation. Realistic expectations matter more than hope alone.
Peripheral nerves—the nerves carrying signals between your spinal cord and the rest of your body—can be injured by trauma (crush, laceration, stretch), surgery, ischaemia (loss of blood flow), infection, or chronic compression. When a nerve is damaged, two things happen: the axon—the long extension of the nerve cell that carries electrical signals—breaks, and the supporting cells around it (Schwann cells) die or become inflamed.
Mesenchymal stem cells (MSCs)—the cell type used in our clinic's protocols—do not directly become nerve cells. Instead, they work through paracrine signalling: they release chemical messengers and growth factors that change the environment around the injured nerve. Here are the main mechanisms being studied:
MSC research in nerve injury spans over 15 years of clinical investigation. The evidence falls into three categories: promising laboratory findings, small human trials with encouraging signals, and important limitations to acknowledge.
Laboratory studies consistently show that MSC application near injured nerves reduces inflammation, supports nerve cell survival, and in some cases accelerates axon regrowth in animal models. Human trials are smaller and more recent. A 2021 clinical trial involving patients with crush injuries to peripheral nerves reported that MSC injection at the injury site, combined with conventional care, was associated with faster functional recovery and better sensory restoration compared to standard treatment alone. However, the trial was small (fewer than 30 patients per group), and the improvement, while measurable, was not dramatic—it was modelled as accelerating recovery by weeks to a few months, not reversing a permanently lost function.
Spinal cord injury is more complex than peripheral nerve injury because the spinal cord cannot regenerate in the way peripheral nerves can. Several clinical trials have investigated MSC infusion for spinal cord injury. A 2019 phase II trial in chronic incomplete spinal cord injury reported modest improvements in motor and sensory scores, with benefits appearing over 6–12 months. Importantly, no dramatic recoveries of lost function were observed; the benefit appeared to be slowing further decline and modest functional gains. Safety data showed no adverse events attributed to the MSC treatment itself, though the population already carried significant medical complexity.
Peripheral neuropathy—damage to the small nerve fibres that carry pain and temperature sensation—affects millions of patients with diabetes, chemotherapy exposure, and idiopathic causes. A 2020 randomised controlled trial in diabetic peripheral neuropathy reported that MSC infusion, compared to placebo infusion, was associated with improved sensation scores and reduced neuropathic pain at 6 and 12 months. However, the improvement was moderate—patients still had neuropathy, but severity decreased. Again, MSC therapy appeared to modulate the underlying inflammatory environment rather than 'cure' the neuropathy.
It is crucial to be honest about what remains uncertain. MSC therapy for nerve injury shows biological promise and early encouraging signals, but several limitations constrain current confidence:
Candidate selection is crucial. Not every patient with nerve injury will benefit equally, and some patients should not undergo MSC therapy at all. Our medical team considers the following:
You begin with a detailed consultation—in person or by video if you're abroad—with our neurologist or orthopaedic specialist. We review your injury history, imaging, current symptoms, medications, and previous treatments. We may request additional nerve conduction studies or MRI if records are not recent. The goal is to confirm that MSC therapy is a reasonable and safe next step for you, and to set realistic expectations about what improvement might look like.
If you are deemed suitable, we discuss the planned MSC dose, administration route (usually intravenous infusion combined with local injection near the injury if accessible, or intrathecal injection for spinal cord injury), and timing. Most protocols involve a single MSC infusion session, though some patients may benefit from a second session at 6–8 weeks depending on their response and symptoms.
We use umbilical cord-derived allogeneic MSCs (not autologous—meaning they come from donated cord tissue, not from your own fat or bone marrow). These cells are cultured, expanded, and cryopreserved at -196°C. Before each treatment, thawed cells are assessed for viability (typically >90%), sterility, endotoxin levels, and identity markers (CD73+, CD90+, CD105+). Documentation is complete and available to you. This is not an unregulated or experimental cell product—it is processed under GMP standards and Turkish Ministry of Health (TİTCK) oversight.
The session usually lasts 2–3 hours. For peripheral nerve injury, you may receive both an intravenous infusion (to deliver MSCs systemically and reduce general inflammation) and a local injection near the nerve injury site (guided by ultrasound when possible). For spinal cord injury, MSCs may be delivered via intrathecal injection (into the cerebrospinal fluid surrounding the spinal cord). For peripheral neuropathy, infusion is the primary route. You remain awake and monitored throughout. Most patients report minimal discomfort.
After the session, we schedule follow-up visits at 1 month, 3 months, and 6 months. At each visit, we assess your symptoms, perform functional testing when relevant (grip strength, sensation testing, pain scales), and discuss your physiotherapy progress. Many patients continue to improve between months 3 and 12, so long-term follow-up is important. We encourage you to continue conventional care—physiotherapy, pain management, orthopaedic follow-up—throughout this period.
The source and quality of stem cells matter enormously. Here's what you need to know about ours:
Timelines for Improvement
Because nerve regeneration is slow and often incomplete, realistic improvement includes:
No medical treatment is risk-free. Here are the risks and limitations of MSC therapy for nerve injury:
Many of our patients travel from Europe, North America, the Middle East, and Australia to receive treatment. Here's what to expect:
Most international patients spend 3–7 days in Istanbul: 1–2 days for initial assessment and imaging review, 1 day for the treatment session, and 1–2 days post-treatment before flying. Some patients extend their stay to allow for rest; others compress it if they are experienced travellers and low-risk.
Turkey offers visa-on-arrival or e-visa for most nationalities. Our coordination team assists with travel planning and can recommend accommodation near the clinic.
MSC therapy for nerve injury in Istanbul costs between €8,000 and €15,000 depending on the protocol (peripheral vs. spinal cord, single vs. dual infusion). This includes cell processing, physician consultation, imaging review, and the treatment session itself. Follow-up assessments are charged separately. Most international patients find the total cost substantially lower than private regenerative medicine in their home countries, though cost should never be the primary decision factor—medical suitability and clinic quality matter more.
After your return home, you will need ongoing follow-up. We provide detailed reports to your local physician and remain available for video consultation. However, you should also arrange follow-up with a local neurologist or physiotherapist to monitor your progress and manage conventional care (pain management, rehabilitation). MSC therapy is not a substitute for local medical oversight.
A critical question many international patients ask: if this treatment is not available in my home country, is it legal for me to receive it abroad?
Nerve regeneration is slow by biology. Most patients notice changes between weeks 4–12; more substantial improvements often emerge by month 6. Some continue improving up to a year. If no change is evident by month 4, further improvement is less likely, though it is not impossible.
In severe nerve injuries, complete restoration of lost function is rare—with or without stem cell therapy. MSC therapy may accelerate recovery, reduce pain, and support protective sensation, but it does not guarantee return to pre-injury function. Realistic expectation is meaningful but partial recovery.
No. If you have a completely severed nerve that requires surgical repair (nerve graft or transfer), surgery should proceed. MSC therapy may then support recovery after surgery, but it does not replace the need for surgical nerve repair when indicated.
We treat patients from age 18 onwards. Older age alone does not disqualify you, but overall health, comorbidities, and ability to tolerate the procedure matter. Patients in their 80s can be suitable if they are otherwise medically stable.
Most protocols involve a single MSC session. Some patients benefit from a second session at 6–8 weeks if the first response is partial and clinical assessment supports re-treatment. Conventional physiotherapy, pain management, and orthopaedic follow-up should continue regardless. No "booster" regimen is standard; each patient's plan is individualised.
Not every patient responds meaningfully. If after 6 months you have noticed no change, MSC therapy did not work for you—and that is an honest outcome. You should then explore or continue other options: updated surgical consultation, advanced pain management, spasticity treatment, or clinical trial enrollment elsewhere. Our role is to give you honest assessment and realistic expectations, not to promise results we cannot guarantee.
Stable diabetes, hypertension, and other chronic conditions do not automatically disqualify you. MSC therapy has been studied in diabetic patients with peripheral neuropathy and shows a reasonable safety profile. However, uncontrolled diabetes, active infection, or severe organ dysfunction may make treatment inadvisable. Individual clinical assessment is essential.
Recent publications have focused on optimising MSC dose, timing, and combination protocols. Some trials are combining MSC therapy with rehabilitation protocols—early data suggests that physiotherapy after MSC infusion may amplify benefits. Research is also exploring whether MSC-derived exosomes (the small particles released by MSCs) might achieve similar benefits with less biological burden. This is still investigational, but it reflects the field's movement toward precision and optimisation rather than one-size-fits-all protocols.
Stem cell therapy for nerve damage is a clinically supervised, evidence-informed regenerative approach with over 15 years of research supporting its biological rationale. Early data from human trials suggests that MSC infusion may accelerate nerve recovery, reduce pain, and support functional improvement—but benefits are modest and not universal. This is not a miracle treatment, and it is not approved or standard-of-care in most countries. It is an option to consider if you have exhausted conventional approaches, understand the realistic outcomes, and meet medical eligibility criteria.
If you are exploring stem cell therapy for multiple sclerosis, Parkinson's disease, or other neurological conditions, our clinic also offers specialised protocols for those indications. Learn more about our evidence-based approach to
Stem Cell Therapy for Nerve Damage and Nerve Regeneration: Evidence, Safety and Realistic Outcomes